LDS/Medical Tests/Phenobarbital, Serum or Plasma

Phenobarbital, Serum or Plasma

Phenobarbital is a barbiturate that is most commonly used to control most types of seizures except for petit mal seizures. Like other antiepileptic drugs, it is a nervous system depressant; it has also been used as an antidepressant, and in some cases for treating insomnia. Phenobarbital is taken orally in either a pill form, or a liquid. It is metabolized by the liver and has a half-life between 50 and 120 hours depending on individual metabolism. Phenobarbital circulates through the body with roughly fifty percent bound to protein. Bioavailability for adults and children is greater than 90 percent, while neonates show only around 80 percent. Therapeutic range for Phenobarbital when used for treating epilepsy is 15 – 40 µg /mL, with toxic effects seen when serum levels are >60 µg /mL.

Phenobarbital stimulates the liver to activate liver enzymes, thus enhancing the metabolism of some other drugs. There are several drugs which affect Phenobarbital metabolism, including phenytoin (results in lower phenobarbital levels due to drug interaction) and valproic acid (results in higher phenobarbital levels due to inhibition of metabolism).

Ethanol (found in alcoholic beverages) stimulates liver enzymes, which enhances the metabolism of Phenobarbital, which then lessens the effectiveness of Phenobarbital and may cause adverse effects. As with other antiepileptic drugs, Phenobarbital has been shown to decrease the effectiveness of some oral contraceptives. In adults toxicity manifests central nervous system depression, which may include nystagmus (abnormal eye movement), ataxia (lack of muscle coordination), dysarthria (abnormal speech).

  • Monitor patients receiving Phenobarbital therapy
  • Aid in diagnosing/monitoring Phenobarbital overdose and prevention of Phenobarbital toxicity

Present in:

  • Serum toxicity with Phenobarbital
  • Patient taking Phenobarbital

Absent in:

  • Patient not taking (but expected to take) Phenobarbital
Clinical Status mcg/mL µmol/L
Therapeutic concentration 15–40 65–172
Toxic concentration (slowness, ataxia, nystagmus) 35–80 151–345
Coma with reflexes 65–117 280–504
Coma without reflexes >100 >431
Enzyme immunoassay (EIA), Fluorescent polarization immunoassay (FPIA), High performance liquid chromatography (HPLC), Gas chromatography/mass Spectrophotometry (GC/MS).

Serum (Red top) preferred. Plasma EDTA (Lavender), Citrate (Light Blue) Plasma Heparin (Green). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 30 days
Liver Function Testing, CBC (Complete Blood Count). Other therapeutic drug testing such as phenytoin and valproic acid if suspected.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Indian J Dermatol Venereol Leprol. 2011 Jan-Feb;77(1):7-15. PMID: 21220873
  • Contraception. 2011 Jan;83(1):16-29. Epub 2010 Sep 15. PMID: 21134499
  • Bishop ML, Duben-Engelkirk JL, Fody EP. Clinical Chemistry Principles, Procedures, Correlations. Philadelphia. Lippincott (1996).
  • Lehmann CA. Saunders Manual of Clinical Laboratory Science. Philadelphia. W.B. Saunders Company (1998)
  • Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757